Format

Send to

Choose Destination
Arq Neuropsiquiatr. 2016 Aug;74(8):650-2. doi: 10.1590/0004-282X20160090.

Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis.

Author information

1
Universidade Metropolitana de Santos, Departamento de Neurologia, Santos SP, Brasil;
2
Universidade Federal do Estado do Rio de Janeiro, Departamento de Neurologia, Rio de Janeiro RJ, Brasil;
3
Pontifícia Universidade Católica do Rio Grande do Sul, Departamento de Neurologia, Porto Alegre RS, Brasil;
4
Clinica de Neurologia e Endocrinologia (CLINEN), Departamento de Neurologia, Brasília DF, Brasil;
5
Universidade Estadual de Campinas, Departamento de Neurologia, Campinas SP, Brasil;
6
Pontifícia Universidade Católica Sorocaba, Departamento de Neurologia, Sorocaba SP, Brasil;
7
Universidade Federal Fluminense, Departamento de Neurologia, Niterói RJ, Brasil;
8
Hospital de Base do Distrito Federal, Departamento de Neurologia, Brasília DF, Brasil;
9
Universidade Positivo, Departamento de Neurologia, Curitiba PR, Brasil.

Abstract

OBJECTIVE:

To assess safety of the switch between natalizumab and fingolimod without a washout period.

METHODS:

Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed.

RESULTS:

After a median period of nine months from the medication switch, there were no safety issues to report. The patients had good disease control and no adverse events were reported.

CONCLUSION:

Washout may not be necessary in daily practice when switching from natalizumab to fingolimod. Expertise on multiple sclerosis management, however, is essential for drug switching.

PMID:
27556377
DOI:
10.1590/0004-282X20160090
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online
Loading ...
Support Center